Skip to Content

Fluvastatin Dosage

Applies to the following strength(s): 20 mg ; 40 mg ; 80 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Hyperlipidemia

Immediate Release Capsules:
-Low-density lipoprotein cholesterol (LDL-C) reduction to a goal of 25% or greater: Initial dose of 40 mg orally once a day in the evening or 40 mg orally twice a day
-LDL-C reduction to a goal of less than 25%: Initial dose of 20 mg orally once a day
-Maintenance dose: 20 mg to 80 mg per day

Comments:
-Two 40 mg immediate release capsules should not be taken at one time.

Extended Release Tablets:
80 mg orally once a day, at any time of day

Use: As an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and apolipoprotein B (Apo B) levels, and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb)

Usual Adult Dose for Hyperlipoproteinemia Type IIa (Elevated LDL)

Immediate Release Capsules:
-Low-density lipoprotein cholesterol (LDL-C) reduction to a goal of 25% or greater: Initial dose of 40 mg orally once a day in the evening or 40 mg orally twice a day
-LDL-C reduction to a goal of less than 25%: Initial dose of 20 mg orally once a day
-Maintenance dose: 20 mg to 80 mg per day

Comments:
-Two 40 mg immediate release capsules should not be taken at one time.

Extended Release Tablets:
80 mg orally once a day, at any time of day

Use: As an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and apolipoprotein B (Apo B) levels, and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb)

Usual Adult Dose for Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL)

Immediate Release Capsules:
-Low-density lipoprotein cholesterol (LDL-C) reduction to a goal of 25% or greater: Initial dose of 40 mg orally once a day in the evening or 40 mg orally twice a day
-LDL-C reduction to a goal of less than 25%: Initial dose of 20 mg orally once a day
-Maintenance dose: 20 mg to 80 mg per day

Comments:
-Two 40 mg immediate release capsules should not be taken at one time.

Extended Release Tablets:
80 mg orally once a day, at any time of day

Use: As an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and apolipoprotein B (Apo B) levels, and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb)

Usual Adult Dose for Dyslipidemia

Immediate Release Capsules:
-Low-density lipoprotein cholesterol (LDL-C) reduction to a goal of 25% or greater: Initial dose of 40 mg orally once a day in the evening or 40 mg orally twice a day
-LDL-C reduction to a goal of less than 25%: Initial dose of 20 mg orally once a day
-Maintenance dose: 20 mg to 80 mg per day

Comments:
-Two 40 mg immediate release capsules should not be taken at one time.

Extended Release Tablets:
80 mg orally once a day, at any time of day

Use: As an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and apolipoprotein B (Apo B) levels, and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb)

Usual Adult Dose for Prevention of Cardiovascular Disease

Immediate Release Capsules:
-LDL-C reduction to a goal of 25% or greater: Initial dose of 40 mg orally once a day in the evening or 40 mg orally twice a day
-LDL-C reduction to a goal of less than 25%: Initial dose of 20 mg orally once a day
-Maintenance dose: 20 mg to 80 mg per day

Comments:
-Two 40 mg immediate release capsules should not be taken at one time.

Extended Release Tablets:
80 mg orally once a day, at any time of day

Use: For use in patients with clinically evident coronary heart disease to reduce the risk of undergoing coronary revascularization procedures and to slow the progression of coronary atherosclerosis

Usual Pediatric Dose for Heterozygous Familial Hypercholesterolemia

10 to 16 years:
-Initial dose: 20 mg orally once a day
-Maintenance dose: 20 mg to 80 mg per day
-Maximum dose: 40 mg twice a day (immediate release); 80 mg once a day (extended release)

Comments:
-Dose adjustments up to the maximum daily dose should be made at 6 week intervals and should be individualized based on goals of therapy.

Use: As an adjunct to diet to reduce Total-C, LDL-C, and ApoB levels in adolescent boys and adolescent girls who are at least 1 year post-menarche, 10 to 16 years of age, with heterozygous familial hypercholesterolemia and the following findings are present: LDL-C remains at 190 mg/dL or greater, or LDL-C remains at 160 mg/dL or greater and there is a positive family history of premature cardiovascular disease (CVD) or 2 or more other CVD risk factors are present

Renal Dose Adjustments

Mild to moderate renal dysfunction: No adjustment recommended.
Severe renal dysfunction: Doses greater than 40 mg have not been studied and should therefore be used with caution

Liver Dose Adjustments

Active liver disease (including unexplained persistent elevations in hepatic transaminase levels): Contraindicated

Dose Adjustments

Concomitant use with Cyclosporine or Fluconazole:
-Maximum dose: 20 mg orally twice a day

Precautions

Safety and efficacy have not been established in patients younger than 10 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Take with or without food
-Do not break, crush, or chew tablets or open capsules prior to administration
-Do not take two 40 mg capsules at one time

Storage requirements:
-Dispense in tight container; protect from light.

General:
-This drug has not been studied in conditions where the major abnormality is elevation of chylomicrons, very low density lipoprotein, or intermediate-density lipoprotein (i.e., hyperlipoproteinemia Types I, III, IV, or V).
-This drug should be used in addition to a diet restricted in saturated fat and cholesterol only when response to diet and other nonpharmacologic measures alone has been inadequate.

Monitoring:
-Hepatic: Measure liver enzymes prior to initiation and repeat if signs/symptoms of liver injury occur.
-Metabolic: Measure lipid panels 4 weeks after initiation and upon dose adjustments.

Patient advice:
-Report immediately any unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever, or if muscle signs/symptoms persist after discontinuing therapy.
-Promptly report any symptoms that may be indicative of liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice.
-Contraceptive methods should be used while taking this drug.
-Talk to your health care provider if they are pregnant, planning to become pregnant, or breastfeeding; this drug is not recommended for use during pregnancy or in nursing mothers.

Hide